BMO Capital on Bristol-Myers Squibb (BMY): 'LIBREXIA-ACS Discontinuation Places More Weight on Remaining Programs'
Tweet Send to a Friend
BMO Capital analyst Evan David Seigerman reiterated a Market Perform rating and $47.00 price target on Bristol-Myers Squibb Co. (NYSE ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
